777P A phase II study of the efficacy of olaparib maintenance monotherapy for patients with HRD-positive, newly diagnosed, advanced, high-grade ovarian cancer, evaluated by whole-exome sequencing (MSBM-OL)
Katsutoshi Oda(The University of Tokyo), K. Hasegawa(Saitama Medical University), Masataka Takenaka(Jikei University School of Medicine), Keiko Ueda(Japan Society for the Promotion of Science), Yosuke Konno(Hokkaido University of Science), Shinya Sato(Tokuyama (Japan)), Shoji Nagao(Saitama Medical University), Daisuke Shintani(Saitama Medical University), Masahiro Kagabu(Iwate Medical University), J. Hamanishi(Kyoto University), Kenji Tatsuno(The University of Tokyo), Noriomi Matsumura(Kindai University), Kosuke Yoshihara(Niigata University), Akira Nishijima(The University of Tokyo), Takashi Aoki(Epson (United States)), Masahiko Mori(Meguro Parasitological Museum), Kazunobu Nishimura(X-Fab (Germany)), Hiroyuki Aburatani(The University of Tokyo), Ko Kato(Kitasato University Hospital), Kosuke Kashiwabara(Japan Society for the Promotion of Science)
Cited by 0
Related Papers
Inferring tumour purity and stromal and immune cell admixture from expression data
|Nature Communications|2013|10.7k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
|Nature Genetics|2014|780
A pan-cancer proteomic perspective on The Cancer Genome Atlas
|Nature Communications|2014|641
The landscape of viral associations in human cancers
|Nature Genetics|2020|408